For research use only. PeptaBase is for informational and laboratory research reference only. No medical claims are made and nothing on this site is intended to diagnose, treat, cure or prevent any disease.
PeptaBase
✓500+ PubMed Citations✓Free To Use✓No Account Required
Back to Database
Immune Modulation

Thymosin Alpha-1 Protocol

Dosing & Research

Last Updated: September 4, 2026

Chemical Identity
Molecular Formula
C129H215N33O55
Molecular Weight
3108.3 g/mol
CAS Number
62304-98-7

Antiviral and immunomodulation research, Vaccine adjuvant studies, Oncology adjunct research, T-cell activation

Evidence Level
Human Clinical Data Available
Species Studied
Human • Rat • Mouse
Half-Life
~2 Hours
Administration
Subcutaneous
Frequency
2x Weekly

How It Works

  • Antiviral and immunomodulation research
  • Vaccine adjuvant studies
  • Oncology adjunct research
  • T-cell activation

Dosing Structure

Dose
1.5 mg
Frequency
2x Weekly
Notes
Dose: 0.8-1.6mg twice weekly. Timing: Morning injection preferred. Inject: Abdomen, thigh (rotate sites). Consistent schedule. Break: 4-6 weeks rest after each 8-12 week cycle.

Example Protocols

Dose: 1.5 mg
Frequency: 2x Weekly
Duration: 6-8 weeks
Off Period: Not listed
Calculate dosing →

Find Research Grade Thymosin Alpha-1

Recommended vendors for sourcing research-grade material. PeptaBase does not sell peptides directly.

Vendor One Research Labs

COA Verified

Third-party COA-verified research peptides with published batch testing.

Source Coming Soon

Vendor Two Sciences

Purity Tested

US-based research compound supplier with independent purity testing.

Source Coming Soon

Vendor Three Peptide Co.

Bulk research peptide sourcing with batch-level documentation.

Source Coming Soon
View all recommended vendors →

Protocol Notes

•
Dose: 0.8-1.6mg twice weekly.
•
Timing: Morning injection preferred.
•
Inject: Abdomen, thigh (rotate sites).
•
Consistent schedule.
•
Break: 4-6 weeks rest after each 8-12 week cycle.

What Is Thymosin Alpha-1?

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide naturally secreted by the thymus gland that acts as a master regulator of immune function. It modulates both innate and adaptive immunity - enhancing T-cell maturation, natural killer cell activity, and dendritic cell function while simultaneously reducing excessive inflammatory signaling. It holds regulatory approval in multiple countries for chronic hepatitis B and C, and is under investigation for COVID-19, sepsis, and cancer immunotherapy.

Research Observations - Not Medical Claims
  • ▸Hepatitis B: A meta-analysis of 14 RCTs (n=899) found Tα1 significantly improved HBeAg seroconversion and HBV DNA suppression vs. controls (PMID: 22922255).
  • ▸COVID-19 severity: Observational data from China (2020) showed Tα1 administration in severe COVID-19 reduced mortality in lymphopenic patients - proposed mechanism involves restoration of exhausted T-cell populations.
  • ▸Sepsis: The ETASS trial and subsequent meta-analyses suggest Tα1 reduces 28-day mortality in sepsis patients, particularly those with immunosuppressed profiles.
  • ▸Cancer immunotherapy adjuvant: Combined with standard chemotherapy, Tα1 has shown improved response rates and reduced immunosuppression in non-small cell lung cancer (NSCLC) trials in China.
  • ▸T-cell activation: Tα1 upregulates MHC class II expression, increases IL-2 production, and promotes Th1 immune polarization - mechanistic studies well-characterized in vitro and in vivo.

Evidence Summary

Human Clinical Data AvailableApproved in 35+ countries as Zadaxin (SciClone) for viral hepatitis - Research use only in US
Evidence StrengthModerate
PreliminaryModerateStrong
Curated Citations3
Largest Study (n)899
Most Recent Study2023
Species Studied
HumanRatMouse

Commonly Researched With

BPC-157
BPC-157's anti-inflammatory and healing properties complement Tα1's immune modulation in recovery and post-infection research protocols.
Epithalon
Both are thymic/bioregulator peptides - Tα1 from thymus gland signaling, Epithalon targeting pineal/longevity pathways; studied together in immunosenescence research.
TB-500
TB-500's systemic healing activity is studied alongside Tα1 in infection recovery and post-injury immune support contexts.

Research & Studies

Loading citations…

Research Feedback

0 approved

For research discussion only. Community feedback is moderated and shown here as aggregated insights after approval.

Related Peptides

ARA-290
Immune Modulation
Cortagen
Immune Modulation
KPV
Immune Modulation
LL-37
Immune Modulation